Continuing Education Activity

Vulvar intraepithelial neoplasia (VIN) is a noninvasive squamous lesion and precursor of squamous cell carcinoma of the vulva. This activity reviews the evidence-based approaches to diagnosing and managing VIN and focuses on current advancements in histopathological classification and risk stratification of VIN lesions. The latest updates in topical therapies, laser interventions, and surgical treatments are discussed. Individualized care plans tailored to patient needs and preferences are emphasized, and emerging research on HPV vaccination and its potential impact on VIN prevention is explored. This activity highlights the role of the interprofessional team in optimizing patient outcomes through early detection of VIN and effective multidisciplinary interventions.

Objectives:

• Apply the 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) classification system to accurately categorize vulvar squamous intraepithelial lesions, distinguishing them from other vulvar conditions.
• Identify the risk factors, etiology, and pathophysiology for both subtypes of VIN.
• Implement appropriate evidence-based preventive measures, treatment, and surveillance protocols for patients with VIN.
• Collaborate with the interprofessional team to provide comprehensive and coordinated care for patients with VIN, optimizing their outcomes and reducing their risk of recurrence.

Introduction

Vulvar intraepithelial neoplasia (VIN) is a noninvasive squamous lesion and precursor of squamous cell carcinoma (SCC) of the vulva. Because there is no screening test for VIN, careful examination and biopsy of its various clinical lesions are essential. VIN lesions can be raised, flat, white, gray, or pigmented; diagnosis is made clinically and confirmed with a biopsy.[1]

In 2015, the International Society for the Study of Vulvovaginal Disease (ISSVD) proposed this classification for vulvar squamous intraepithelial lesions (SILs):[2]

• Low-grade SIL (LSIL) of the vulva 

  • Vulvar LSIL, flat condyloma, or human papillomavirus (HPV) effect
  • Previously referred to as VIN 1
• High-grade SIL (HSIL) of the vulva

  • Vulvar HSIL, VIN usual type (uVIN)
  • Previously referred to as VIN 2 and VIN 3
• Differentiated VIN (dVIN) 

  • Previously referred to as VIN simplex type

Etiology

There are 2 different types of VIN: uVIN, which is associated with HPV, and dVIN, which is associated with chronic inflammation. The classification of VIN is based on histology and does not involve HPV testing. 

dVIN

• Accounts for only 5% (approximately) of all VIN cases
• Correlates with a greater potential for progression to invasive SCC [3] 

uVIN 

• An HPV lesion
• Increases the likelihood of other anogenital cancers [3] 

Low-grade lesions are not considered premalignant and are treated as condyloma. HPV prevalence in VIN (HSIL) has been reported in 72% to 100% of cases. HPV-16 is the most common HPV type.[4]

Epidemiology

The incidence of VIN is higher in White women than non-White women, with the highest reported incidence occurring during the fourth decade of life.[3] uVIN is more common in younger women and can even occur in adolescent girls (average age at presentation, 40 years), whereas dVIN is more common in older women (average age at presentation, 60 years).[3][5][6] 

HPV DNA is present in most VIN and SCC; thus, VIN is considered an HPV-associated disease.[3] The 3 most common types of HPV found in VIN lesions are 16, 18, and 33.[3] Other risk factors for VIN include multiple sexual partners, cigarette smoking, and immunocompromised states such as those found in patients with HIV infection, autoimmune diseases, and organ transplants.[5][6][7] Risk factors for dVIN include vulvar dermatoses such as lichen sclerosis. 

A recent study from the Netherlands of 1100 patients with high-grade VIN showed an increased incidence of both HSIL and dVIN.[8] This change may be due to greater awareness of VIN, which may have led to increased vulvar biopsies.[8] The study also showed the 10-year cumulative risk of vulvar cancer, which was significantly greater for dVIN than for HSIL.[8] Another study put the risk of vulvar cancer in dVIN between 33% and 86%, with time to progression between 9 and 23 months.[9]

Table

Table. Characteristics of uVIN and dVIN.

Adapted from Kavitha A, Deeksha P.[10]

Pathophysiology

HPV is a single-stranded DNA virus. When the body fails to produce an effective immune response to high-risk HPV subtypes, uVIN occurs. The viral DNA integrates into host cells, producing oncoproteins E6 and E7, which interfere with normal cellular function.[3] Mutations in the tumor suppressor genes p53 and PTEN and microsatellite instability have also been demonstrated in HPV-independent carcinogenesis.[3][5][6] In contrast, dVIN appears to be related to chronic oxidative genetic damage that promotes similarly aberrant cellular function. Lichen sclerosis and lichen planus are examples of chronic, inflammatory changes in the normal epithelium that are associated with SCC of the vulva.[3][5] 

Histopathology

The histological feature necessary for diagnosing VIN is the proliferation of atypical basal cells. The 5 criteria for atypia are basal layer involvement, enlarged nuclei, hyperchromasia, pleomorphic cells, and increased numbers of mitotic figures.[3] Aside from atypia, both uVIN and dVIN have distinctive features.

In uVIN, proliferation begins at the basal layer and involves partial to full thickness of the squamous epithelium.[5] The uVIN lesions exhibit basal cells with large, dark nuclei and small amounts of basophilic cytoplasm.[3] However, approaching the surface epithelium, atypical basaloid cells may mature to develop an abundant eosinophilic cytoplasm.[3] The more mature squamous cells often display a cytopathic change termed koilocytosis.[3] Warty and basaloid subtypes of uVIN are described; both forms are premalignant and treated identically.[3]

A high oncogenic potential exists with dVIN, and dVIN characteristics are more subtle.[5] Key features of dVIN are a thickened epidermis, parakeratosis, basal nuclear atypia, and premature maturation above the basal layer. These premature cells possess eosinophilic cytoplasm, intracellular prickles, large nuclei, and prominent nucleoli.[3] The relatively high degree of differentiation often present in dVIN lesions can be mistakenly diagnosed as benign.[5]

Immunohistochemistry markers can be used to differentiate between uVIN and dVIN. P53 positivity and p16 negativity support a dVIN diagnosis, whereas the converse supports a uVIN diagnosis.[3][5][6] VIN with a TP53 mutation may be a significant risk factor for both VIN recurrence and the development of invasive disease.[10]

History and Physical

VIN is a clinical diagnosis.[3] There is no routine screening test for VIN; however, abnormal cytology or a positive high-risk HPV test used in cervical cancer screening warrants an independent visual assessment of the vulva.[3] Acetic acid alone is not recommended for diagnosis because the whitened color of observed lesions is not specific to vulvar intraepithelial neoplasia.[3] One should note the following on examination of the vulva for lesions seen: location, number, size, shape, color, and thickness.

VIN is generally multifocal. Lesions may be raised, verrucous, and white; however, they may also be red, gray, or pigmented. There is no pathognomic appearance, hence the need for a biopsy of any abnormal vulvar lesion. Different patterns may be present in the same patient.[11]

Evaluation

uVIN and dVIN are clinically dissimilar: uVIN is commonly multifocal and elevated, found around the introitus and labia majora;[3] dVIN lesions demonstrate poorly demarcated pink or white plaques (often associated with lichen sclerosis or lichen planus) and are refractory to medical therapy.[3][6] 

A colposcopic examination of the vulva can be performed to complement a visual exam; a hand lens with magnification can also be used. Toluidine solution to identify VIN (Collins test) has low specificity and is not recommended.[12] 

All portions of the vulva, including the labia majora and minora, vestibule, clitoris, terminal urethra, perineum, and perianal area, should be examined. If high-grade lesions are discovered, an examination and cytology of the anal canal may be necessary. Up to 18% of patients with vulvar HSIL may have anal lesions.[11] Any observed vulvar lesions require a biopsy to determine appropriate treatment.[3]

Treatment / Management

The ideal treatment of VIN involves the complete destruction of the lesion, symptom improvement, and preservation of vulvar function.[3] Treatment options include surgical, medical, or expectant management. Prevention has, and will ultimately continue to, decrease the disease burden.

uVIN

Excisional Treatment

Cold knife surgery and loop electrosurgical excision procedure (LEEP) are the preferred treatments for uVIN. The recommendations for negative surgical margins are a 5-mm peripheral margin and a 4-mm deep margin. However, margin status does not predict the risk of invasive or recurrent disease.[3]

An alternative treatment is CO₂ laser ablation, but vaporization of the diseased tissue precludes a pathologic specimen.[3] Although the advantage of laser ablation is the preservation of normal anatomy with less scarring, the cost is an increased risk of recurrence.[7]

Medical Treatment

Imiquimod is an immune-modifying drug that induces proinflammatory cytokines with antiviral and antitumor properties and enhances innate and cell-mediated immunity against HPV.[3] Trials using Imiquimod have demonstrated efficacy comparable to surgical results, and it can be an adjunct to excision with positive margins or recurrent cases.[13] Local irritation, erythema, and erosions may occur. Complete response rates in database reviews were 51%, and partial response rates were 25%.[14]

Other medical options for treatment are utilized less often. Cidofovir is an acyclic nucleoside analog with antiviral properties that promotes apoptosis of HPV-infected cells.[3] Photodynamic therapy is an option in conjunction with nonthermal light to generate oxygen-induced cellular death.[3] 

dVIN

Excisional Treatment

dVIN is associated with lichen sclerosis and invasive disease (specifically, SCC of the vulva).[15] Recurrence rates for dVIN are much higher than those for uVIN.[16] Treatment of these lesions should include surgical excision with a scalpel, LEEP, or laser. Wide local excision is preferable as the initial treatment.[17][18][19]

Expectant Management

Spontaneous regression is reported in uVIN but is adversely influenced by the increasing age of the patient, clinical presentation with chronic immunosuppression and multifocal disease, and the longer duration of the lesion.[3] Close surveillance of these patients is required even after spontaneous regression occurs. Women younger than 35 years have a higher rate of regression. Pregnancy has been reported to increase both spontaneous regressions and the progression of premalignant vulvar lesions.[5]

Preventative Management

HPV vaccination has reduced the incidence of VIN in young women.[5] However, HPV vaccination is designed as a prophylactic measure, not a treatment for confirmed lesions.[6]

Differential Diagnosis

Any observed lesion of the vulva requires a biopsy for diagnosis. Benign lesions include common dermatopathology such as lichen simplex, lichen sclerosis, or lichen planus. Vulvar lesions may also result from infections such as vestibulitis, candidiasis, or herpes. Genital warts, psoriasis, condyloma acuminata, and seborrheic keratosis are also included in the differential diagnosis. VIN is a preinvasive lesion that may appear similar to these more common skin changes or common malignancies such as basal cell carcinoma, SCC, Paget disease, or melanoma. Treatment without biopsy confirmation risks progression and delays the diagnosis of potential malignancy.[20]

Prognosis

The prognosis of biopsy-confirmed VIN that receives prompt treatment is uniformly good; there is rarely progression to invasive cancer unless treatment is declined or markedly delayed. Without treatment, uVIN can progress to invasive cancer in 6 to 7 years, whereas in untreated dVIN, vulvar cancer can result in 2 to 4 years.

Long-term surveillance is necessary, given the high recurrence rate after any treatment and the possibility of long-term recurrences. Follow-up is recommended every 6 to 12 months (for at least 5 years for uVIN, indefinitely for dVIN).

A third to one-half of patients may have a recurrence of their disease, and 25% of patients can experience late recurrences. Risk factors for recurrence include large lesion size, age (50 years and older), positive excision margins, multifocal disease, immunosuppression, and tobacco use.[21][10] 

Complications

The most severe complication of untreated VIN is progression to invasive carcinoma. Malignant disease of the vulva necessitates more involved radical resection, commonly associated with perioperative morbidities such as pain, infection, wound dehiscence, and altered vulvar appearance. Surgical resection complications depend on the treated lesions' location, distribution, and size. Topical therapies may result in irritation, burning, or ulceration.

Deterrence and Patient Education

In age-appropriate patients, the use of the HPV vaccine should be discussed to prevent lower genital tract disease, including condyloma and uVIN.[22] Theoretically, the 9-valent HPV vaccination can reduce uVIN risk by 80% to 90%. Immunization does not decrease the risk of dVIN.

Patients with a history of genital warts or previous uVIN should be encouraged to stop smoking. The need for continued life-long observation is also an essential part of patient education.

Effective and timely treatment of vulval skin disorders such as lichen sclerosis and lichen planus may reduce the risk of dVIN and vulvar cancer. 

Pearls and Other Issues

There are 2 types of VIN: uVIN related to HPV infection and dVIN related to chronic oxidative damage. uVIN is multifocal and multicentric, whereas dVIN is unifocal and difficult to distinguish from benign lesions.[3] dVIN only accounts for a small percentage of all VIN lesions and has a higher association with invasive cancer than uVIN. Most uVIN is related to HPV-16; however, there are reports of other high-risk HPV subtypes in histologically confirmed uVIN.[3][5][6] Failure of the immune system to produce an immune response against HPV allows viral DNA to become integrated into the host DNA, which can promote disruption of cellular function and transformation, causing VIN.

Enhancing Healthcare Team Outcomes

When the primary care clinician, internist, or nurse practitioner suspects a patient may have VIN, referral to a gynecologist is recommended. The diagnosis is made clinically with inspection and biopsy, often utilizing immunohistochemistry. Treatment depends on lesion type, location, size, and extent of disease. Lifelong surveillance is essential since resection of individual lesions does not guarantee the prevention of invasive cancer.[3] 

Healthcare professionals should strongly encourage HPV vaccination to reduce the incidence of VIN and invasive vulvar cancer.[3] VIN prevention and management, including long-term follow-up care, is best accomplished by an interprofessional team that includes physicians, advanced care practitioners, and nurses to achieve the best possible patient outcomes. 

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Committee Opinion No. 675: Management of Vulvar Intraepithelial Neoplasia: Correction. Obstet Gynecol. 2017 Jan;129(1):209. [PubMed: 28092302]

2.

Bornstein J, Bogliatto F, Haefner HK, Stockdale CK, Preti M, Bohl TG, Reutter J., ISSVD Terminology Committee. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions. Obstet Gynecol. 2016 Feb;127(2):264-8. [PubMed: 26942352]

3.

Preti M, Scurry J, Marchitelli CE, Micheletti L. Vulvar intraepithelial neoplasia. Best Pract Res Clin Obstet Gynaecol. 2014 Oct;28(7):1051-62. [PubMed: 25106700]

4.

Lebreton M, Carton I, Brousse S, Lavoué V, Body G, Levêque J, Nyangoh-Timoh K. Vulvar intraepithelial neoplasia: Classification, epidemiology, diagnosis, and management. J Gynecol Obstet Hum Reprod. 2020 Nov;49(9):101801. [PubMed: 32417455]

5.

Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology. 2013 Jan;62(1):161-75. [PubMed: 23190170]

6.

Léonard B, Kridelka F, Delbecque K, Goffin F, Demoulin S, Doyen J, Delvenne P. A clinical and pathological overview of vulvar condyloma acuminatum, intraepithelial neoplasia, and squamous cell carcinoma. Biomed Res Int. 2014;2014:480573. [PMC free article: PMC3956289] [PubMed: 24719870]

7.

Wallbillich JJ, Rhodes HE, Milbourne AM, Munsell MF, Frumovitz M, Brown J, Trimble CL, Schmeler KM. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecol Oncol. 2012 Nov;127(2):312-5. [PMC free article: PMC3632361] [PubMed: 22867736]

8.

Thuijs NB, van Beurden M, Bruggink AH, Steenbergen RDM, Berkhof J, Bleeker MCG. Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma. Int J Cancer. 2021 Jan 01;148(1):90-98. [PMC free article: PMC7689827] [PubMed: 32638382]

9.

Vieira-Baptista P, Pérez-López FR, López-Baena MT, Stockdale CK, Preti M, Bornstein J. Risk of Development of Vulvar Cancer in Women With Lichen Sclerosus or Lichen Planus: A Systematic Review. J Low Genit Tract Dis. 2022 Jul 01;26(3):250-257. [PubMed: 35285455]

10.

Jamieson A, Tse SS, Brar H, Sadownik LA, Proctor L. A Systematic Review of Risk Factors for Development, Recurrence, and Progression of Vulvar Intraepithelial Neoplasia. J Low Genit Tract Dis. 2022 Apr 01;26(2):140-146. [PubMed: 35249976]

11.

Kesić V, Vieira-Baptista P, Stockdale CK. Early Diagnostics of Vulvar Intraepithelial Neoplasia. Cancers (Basel). 2022 Apr 04;14(7) [PMC free article: PMC8997501] [PubMed: 35406594]

12.

Diagnosis and Management of Vulvar Skin Disorders: ACOG Practice Bulletin Summary, Number 224. Obstet Gynecol. 2020 Jul;136(1):222-225. [PubMed: 32590722]

13.

Trutnovsky G, Reich O, Joura EA, Holter M, Ciresa-König A, Widschwendter A, Schauer C, Bogner G, Jan Z, Boandl A, Kalteis MS, Regauer S, Tamussino K. Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial. Lancet. 2022 May 07;399(10337):1790-1798. [PubMed: 35483400]

14.

Mahto M, Nathan M, O'Mahony C. More than a decade on: review of the use of imiquimod in lower anogenital intraepithelial neoplasia. Int J STD AIDS. 2010 Jan;21(1):8-16. [PubMed: 20029061]

15.

van de Nieuwenhof HP, van Kempen LC, de Hullu JA, Bekkers RL, Bulten J, Melchers WJ, Massuger LF. The etiologic role of HPV in vulvar squamous cell carcinoma fine tuned. Cancer Epidemiol Biomarkers Prev. 2009 Jul;18(7):2061-7. [PubMed: 19567503]

16.

Eva LJ, Ganesan R, Chan KK, Honest H, Malik S, Luesley DM. Vulval squamous cell carcinoma occurring on a background of differentiated vulval intraepithelial neoplasia is more likely to recur: a review of 154 cases. J Reprod Med. 2008 Jun;53(6):397-401. [PubMed: 18664055]

17.

Jin C, Liang S. Differentiated Vulvar Intraepithelial Neoplasia: A Brief Review of Clinicopathologic Features. Arch Pathol Lab Med. 2019 Jun;143(6):768-771. [PubMed: 30640512]

18.

Grimm D, Prieske K, Mathey S, Kuerti S, Burandt E, Schmalfeldt B, Woelber L. Superficially invasive stage IA vulvar squamous cell carcinoma-therapy and prognosis. Int J Gynecol Cancer. 2019 Mar;29(3):466-473. [PubMed: 30622111]

19.

Bryan S, Barbara C, Thomas J, Olaitan A. HPV vaccine in the treatment of usual type vulval and vaginal intraepithelial neoplasia: a systematic review. BMC Womens Health. 2019 Jan 07;19(1):3. [PMC free article: PMC6323700] [PubMed: 30616555]

20.

Dockery LE, Soper JT. Vulvar Intraepithelial Neoplasia: A Review of the Disease and Current Management. Obstet Gynecol Surv. 2021 Jan;76(1):55-62. [PubMed: 33506879]

21.

Satmary W, Holschneider CH, Brunette LL, Natarajan S. Vulvar intraepithelial neoplasia: Risk factors for recurrence. Gynecol Oncol. 2018 Jan;148(1):126-131. [PubMed: 29126556]

22.

Issanov A, Karim ME, Aimagambetova G, Dummer TJB. Does Vaccination Protect against Human Papillomavirus-Related Cancers? Preliminary Findings from the United States National Health and Nutrition Examination Survey (2011-2018). Vaccines (Basel). 2022 Dec 10;10(12) [PMC free article: PMC9781459] [PubMed: 36560523]

Disclosure: Michael Ayala declares no relevant financial relationships with ineligible companies.

Disclosure: Mary Fatehi declares no relevant financial relationships with ineligible companies.